• adivo GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • tev.ovida@ofni

Dr. Kathrin Ladetzki-Baehs
Geschäftsführerin / Managing Director

About Adivo

Pet ownership constantly increases and nowadays people are considering their cat or dog as a member of the family. As pets live longer, they develop similar geriatric and civilization diseases as humans but there is a gap in the availability of innovative and specific treatments for serious diseases or chronic conditions in companion animals.

Our mission is to develop novel, species-specific therapeutic antibodies from our proprietary, and state of the art antibody platform. The whole team is very passionate identifying unmet medical needs and supporting veterinary health professionals as well as pet owners in treating dogs & cats with novel highly efficient drugs.

Antibody selection is based on a novel fully synthetic and species-specific phage display technology. Currently used strategies rely on the modification of a single existing molecule in a process that is laborious and prone to failure.  Our platform allows the de-novo identification of a panel of antibodies to select the best in class drug candidate with optimal functionality, developability and low risk of immunogenicity. Our primary goal is to address the medical need in canines, but the technology will be adapted at later stages to other species such as cats or horses.

In addition to our own drug development, we are planning collaborations with pharmaceutical partners from the veterinary field.

What is your motivation?

I am a passionate dog lover and it is exactly this kind of passion for pets that our entire adivo team has in common. In Germany nearly every second household owns a dog or a cat. Today more than ever, our pets are real family members who, due to their increasing life span, develop diseases very similar to those seen in humans. These disorders include chronic inflammatory diseases of the skin, joints and gastrointestinal tract as well as various severe types of cancer. In human medicine, it seems perfectly normal treating diseases with efficient, innovative drugs and therapies, but these possibilities are hardly available in veterinary medicine. Animal owners are asking for, almost demand, new, effective and specific treatment options for their beloved companions in order to improve their quality of life. This is exactly the problem we are addressing.

„Pets make a difference in our life; we should make a difference in theirs. Therefore, we are glad for the opportunity to be the first company at IZB with a veterinary focus.”

Dr. Kathrin Ladetzki-Baehs
Geschäftsführerin / Managing Director